SCHEMBL2525394

SCHEMBL2525394

C=CCC1(c2ccccc2)c2ccccc2CCN1C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 4/20 0.39
HDAC9 Q9UKV0 1/20 0.36
KIF11 P52732 1/20 0.36
SLC6A4 P31645 3/20 0.36
SLC6A3 Q01959 2/20 0.36
SLC6A2 P23975 2/20 0.36
KMT2A Q03164 2/20 0.34
TET3 O43151 1/20 0.34
FBXL19 Q6PCT2 1/20 0.34
CXXC5 Q7LFL8 1/20 0.34
TET1 Q8NFU7 1/20 0.34
KDM2B Q8NHM5 1/20 0.34
CXXC4 Q9H2H0 1/20 0.34
KDM2A Q9Y2K7 1/20 0.34
OPRL1 P41146 1/20 0.33
ATM Q13315 1/20 0.33
RBP4 P02753 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2523832 1.00 SIGMAR1 (0.39) SIGMAR1HDAC9KIF11SLC6A4SLC6A3
SCHEMBL1404036 0.83 MITF (0.39) HDAC9KIF11SLC6A4KMT2A
SCHEMBL6073260 0.83 MITF (0.39) HDAC9KIF11SLC6A4KMT2A
SCHEMBL15355348 0.70 MEN1 (0.39) HDAC9KMT2A
SCHEMBL15355355 0.70 ALDH1A1 (0.43) HDAC9KMT2A
SCHEMBL28703383 0.70 SIGMAR1 (0.39) SIGMAR1KMT2A
SCHEMBL15355309 0.68 ALDH1A1 (0.38) HDAC9KMT2A
SCHEMBL22776858 0.68 CHRM5 (0.34) SIGMAR1HDAC9KMT2A
SCHEMBL2791470 0.67 RAB9A (0.43) SIGMAR1HDAC9KIF11KMT2AOPRL1
SCHEMBL9570551 0.66 SIGMAR1 (0.43) SIGMAR1HDAC9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029587-B1 PROCESS FOR THE PREPARATION OF SOLIFENACIN ZENTIVA AS (CZ) 2015-09-02 EP disclosed
US-8034942-B2 Process for the preparation of solifenacin Zentiva k s. (CZ) 2011-10-11 US disclosed
US-20090203914-A1 PROCESS FOR THE PREPARATION OF SOLIFENACIN ZENTIVA K.S. (CZ) 2009-08-13 US disclosed
EP-2046751-A2 PROCESS FOR PREPARING SOLIFENACIN AND ITS SALTS Dr. Reddy's Laboratories Ltd. (IN) 2009-04-15 EP disclosed
EP-2029587-A2 PROCESS FOR THE PREPARATION OF SOLIFENACIN Zentiva, A.S. (CZ) 2009-03-04 EP disclosed
WO-2008011462-A2 PROCESS FOR PREPARING SOLIFENACIN AND ITS SALTS DR. REDDY'S LABORATORIES LTD. (IN) 2008-01-24 WO disclosed
WO-2007147374-A2 PROCESS FOR THE PREPARATION OF SOLIFENACIN ZENTIVA A.S. (CZ) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203914-A1 PROCESS FOR THE PREPARATION OF SOLIFENACIN OPRL1, CHRNG, CHRM1 SIGMAR1 14/4885HDAC9 3895/4885KIF11 3066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.